Targets for improving tumor response to radiotherapy

Mortezaee, Keywan; Parwaie, Wrya; Motevaseli, Elahe; Mirtavoos-Mahyari, Hanifeh; Musa, Ahmed Eleojo; Shabeeb, Dheyauldeen; Esmaely, Farid; Najafi, Masoud; Farhood, Bagher

doi:10.1016/j.intimp.2019.105847

Cited by 66 publications

(46 citation statements)

References 214 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Importantly, the inhibition of the VEGF pathway helped to prevent the proliferation of hypoxic cells, which is generally regarded as a critical issue for radioresistance. 16,17 Additionally, the activation of the VEGF and VEGFR2 pathway resulted in increased vascular cell permeability, followed by increased interstitial fluid pressure, which aggravated hypoxia. Anti-VEGFR2 was revealed to reduce the avidity of endothelial cells after RT, which was closely associated with relapse following RT (Figure 3).…”

Section: Discussionmentioning

confidence: 99%

Giant Fungated Locally Advanced Breast Carcinoma Responded to Hypofractionated Radiotherapy Combined with Apatinib: A Case Report and Literature Review

Liu

et al. 2021

CMAR

View full text Add to dashboard Cite

Locally advanced breast cancer (LABC) is frequently encountered in clinical practice. Primary systemic therapy is regarded as the cornerstone of LABC management to downstage the disease and enable surgery. However, multiple lines of systemic agents may fail to control tumor growth in a considerable number of patients, and few options remain available for such patients. Here, we present a case of triple-negative, right breast cancer that progressed aggressively despite 3 lines of standard chemotherapy. The patient suffered from severe skin ulceration, bleeding, pain, infection, and fungation. The small-molecular tyrosine kinase inhibitor (TKI) apatinib was initiated, which targets vascular endothelial growth factor receptor 2 (VEGFR2). The patient then underwent hypofractionated irradiation applied to the whole right breast at 40 Gy/8 f. The tumor responded dramatically to this combination, and a near-complete remission (CR) response was achieved 2 months after irradiation. Our case is novel and instructional and demonstrated the efficacy and safety of hypofractionated irradiation combined with antiangiogenesis for the treatment of intractable LABC, shedding light on this difficult situation. In the near future, large-scale clinical trials will be initiated to further explore this issue.

show abstract

Section: Discussionmentioning

confidence: 99%

Giant Fungated Locally Advanced Breast Carcinoma Responded to Hypofractionated Radiotherapy Combined with Apatinib: A Case Report and Literature Review

Liu

et al. 2021

CMAR

View full text Add to dashboard Cite

show abstract

“…72 There is also evidence that cytokines such as TGF-b, IL4 and IL-13 can affect the TME, regulate apoptosis and affect angiogenesis. [73][74][75] In addition, these inflammatory factors may regulate the NF-jB pathway and the activity of immune cells, which may affect the prognosis of the tumour. 76,77 The anticancer effect of NF-jB Recent studies have found that NF-jB also has an inhibitory effect on tumour development.…”

Section: Tumour Microenvironmentmentioning

confidence: 99%

Advances in research on the interaction between inflammation and cancer

et al. 2019

View full text Add to dashboard Cite

Inflammation is the body's response to cell damage. Cancer is a general term that describes all malignant tumours. There are no confirmed data on cancer-related inflammation, but some research suggests that up to 50% of cancers may be linked to inflammation, which has led to the concept of ‘cancer-associated inflammation’. Although some cancer patients do not appear to have a chronic inflammatory background, there might be inflammatory cell infiltration in their cancer tissues. The continuation of the inflammatory response plays an important role in the initiation, promotion, malignant transformation, invasion and metastasis of cancer. Anti-inflammatory therapy has been shown to have some effects on the prevention and treatment of cancer, which supports a pathogenic relationship between inflammation and cancer. This review describes the interaction between inflammation and tumour development and the main mechanism of regulation of the inflammatory response during tumour development.

show abstract

“…With the gradual deepening of understanding of TME, targeting TME compounds to undermine protecting hotbed of tumours have become an effective means of cancer treatment. Large amount of pre‐clinic and clinic study proved the quietly success in targeting angiogenesis, extracellular matrix (ECM) and cells components within TME 14 . In recent years, cell therapies are fast rising and have been proven to have powerful functions and ensured safety.…”

Section: Introductionmentioning

confidence: 99%

Modifying the tumour microenvironment and reverting tumour cells: New strategies for treating malignant tumours

et al. 2020

View full text Add to dashboard Cite

The tumour microenvironment (TME) plays a pivotal role in tumour fate determination. The TME acts together with the genetic material of tumour cells to determine their initiation, metastasis and drug resistance. Stromal cells in the TME promote the growth and metastasis of tumour cells by secreting soluble molecules or exosomes. The abnormal microenvironment reduces immune surveillance and tumour killing. The TME causes low anti‐tumour drug penetration and reactivity and high drug resistance. Tumour angiogenesis and microenvironmental hypoxia limit the drug concentration within the TME and enhance the stemness of tumour cells. Therefore, modifying the TME to effectively attack tumour cells could represent a comprehensive and effective anti‐tumour strategy. Normal cells, such as stem cells and immune cells, can penetrate and disrupt the abnormal TME. Reconstruction of the TME with healthy cells is an exciting new direction for tumour treatment. We will elaborate on the mechanism of the TME to support tumours and the current cell therapies for targeting tumours and the TME—such as immune cell therapies, haematopoietic stem cell (HSC) transplantation therapies, mesenchymal stem cell (MSC) transfer and embryonic stem cell‐based microenvironment therapies—to provide novel ideas for producing breakthroughs in tumour therapy strategies.

show abstract

Targets for improving tumor response to radiotherapy

Cited by 66 publications

References 214 publications

Giant Fungated Locally Advanced Breast Carcinoma Responded to Hypofractionated Radiotherapy Combined with Apatinib: A Case Report and Literature Review

Giant Fungated Locally Advanced Breast Carcinoma Responded to Hypofractionated Radiotherapy Combined with Apatinib: A Case Report and Literature Review

Advances in research on the interaction between inflammation and cancer

Modifying the tumour microenvironment and reverting tumour cells: New strategies for treating malignant tumours

Contact Info

Product

Resources

About